For an adult patient presenting within the 4‑hour window for acute ischemic stroke, which thrombolytic agent should be chosen: alteplase (tPA) or tenecteplase?

Alteplase Remains the Standard Choice for Acute Ischemic Stroke Within 4 Hours

For patients presenting within the 4-hour window for acute ischemic stroke thrombolysis, alteplase (0.9 mg/kg IV over 60 minutes) should be your primary agent, as it has the strongest evidence base with Class I, Level A recommendations across all major stroke guidelines. 1, 2

Evidence-Based Reasoning

Alteplase: The Gold Standard

The 2023 World Stroke Organization guidelines explicitly recommend IV alteplase (0.9 mg/kg, maximum 90 mg over 60 minutes with 10% as initial bolus) for patients treated within 4.5 hours of symptom onset 1. This recommendation carries the highest level of evidence and has been validated across decades of clinical practice and multiple randomized controlled trials.

The 2018 AHA/ASA guidelines similarly provide Class I, Level A recommendations for alteplase within 3 hours and Class I, Level B-R for the 3-4.5 hour window 2. This represents the most robust evidence available for thrombolytic therapy in stroke.

Tenecteplase: An Alternative, Not First-Line

While tenecteplase has emerged as a potential alternative, the evidence hierarchy matters here:

The 2018 AHA/ASA guidelines state that tenecteplase (0.4 mg/kg single IV bolus) "might be considered as an alternative to alteplase in patients with minor neurological impairment and no major intracranial occlusion" (Class IIb, Level B-R) 2. This is notably weaker evidence than alteplase's Class I recommendation.

The largest trial (1,100 subjects) showed tenecteplase failed to demonstrate superiority and had similar safety/efficacy to alteplase, predominantly in patients with minor strokes (median NIHSS 4) without large vessel occlusion 2.

Recent Evidence Updates

More recent studies show promise for tenecteplase:

• The 2024 ORIGINAL trial demonstrated non-inferiority of tenecteplase 0.25 mg/kg to alteplase in Chinese patients (72.7% vs 70.3% achieving mRS 0-1 at 90 days) 3
• The 2023 ESO expedited recommendation suggests tenecteplase 0.25 mg/kg "can be used as a safe and effective alternative" (moderate evidence, strong recommendation) 4
• A 2025 real-world study of 79,550 patients found similar effectiveness and safety between agents 5

However, these studies establish tenecteplase as an alternative, not a superior choice.

Clinical Decision Algorithm

For a patient presenting within 4 hours:

1. Default to alteplase - It has the strongest guideline support and longest track record

2. Consider tenecteplase 0.25 mg/kg if:

   • You have institutional protocols supporting its use
   • The patient has minor stroke (NIHSS ≤4-7) without large vessel occlusion
   • Ease of bolus administration offers logistical advantages
   • Cost considerations are significant (tenecteplase saves ~$40,000 per treatment period) 6

3. Avoid tenecteplase 0.4 mg/kg - The 2023 ESO guidelines explicitly recommend against this dose (low evidence, strong recommendation) 4

Key Practical Considerations

Alteplase Administration

• Dose: 0.9 mg/kg (maximum 90 mg)
• Method: 10% as bolus over 1 minute, remaining 90% infused over 60 minutes
• Time dependency: Every 30-minute delay reduces probability of good outcome by 1.8% 7

Tenecteplase Administration (if chosen)

• Dose: 0.25 mg/kg single IV bolus
• Advantage: Single bolus vs 60-minute infusion
• Time dependency: Similar time-to-treatment relationship as alteplase 7

Common Pitfalls to Avoid

1. Don't delay treatment debating agent choice - Time is brain. If your institution uses alteplase as standard, proceed immediately rather than deliberating
2. Don't use tenecteplase 0.4 mg/kg - This dose lacks supporting evidence and has explicit recommendations against it 4
3. Don't skip thrombolysis if thrombectomy is planned - Give IV thrombolysis first, even if mechanical thrombectomy is being considered 2
4. Don't wait to assess response before thrombectomy - Proceed directly to angiography if large vessel occlusion is suspected 2

The Bottom Line

Alteplase remains the evidence-based standard for acute ischemic stroke thrombolysis within 4 hours. Tenecteplase 0.25 mg/kg represents a reasonable alternative with comparable safety and efficacy, particularly in settings where ease of administration or cost are considerations, but it has not demonstrated superiority. When in doubt, choose alteplase—it has decades of proven benefit and the strongest guideline recommendations.